Highlights
Complement deposition on platelet surfaces, including C1q, C3d, and C4d, was present in a substantial proportion of adults with ITP and showed wide interpatient variability.
Unsupervised clustering separated patients into three biologically distinct groups, including a subgroup with high C3d and C4d deposition that also showed more frequent refractoriness to first-line therapy.
Platelet-associated IgM appeared to track most strongly with the high complement activation phenotype, while platelet-associated IgG was observed in both intermediate and high complement clusters.
Complement activation correlated with increased immature platelets, suggesting a link to heightened platelet turnover rather than a direct relationship with fatigue or circulating C1s activity.
Study Background and Clinical Context
Primary ITP is an acquired autoimmune disorder characterized by isolated thrombocytopenia and bleeding risk due to immune-mediated platelet destruction and impaired platelet production. Clinically, the disease is heterogeneous: some patients respond well to corticosteroids or intravenous immunoglobulin, whereas others develop persistent thrombocytopenia or become refractory to first-line therapy. This variability has made it difficult to predict disease course or tailor treatment early in the disease trajectory.
Complement activation is increasingly recognized as an important amplifier of autoantibody-mediated injury in autoimmune disease. In ITP, antibodies bound to platelet antigens may trigger classical complement pathway activation, which can promote opsonization, phagocytosis, and potentially direct membrane injury. Despite this biologic rationale, the clinical relevance of complement activation in adult ITP has remained uncertain. In particular, it has not been clear whether complement deposition identifies a subgroup with more severe disease, greater platelet turnover, or reduced responsiveness to standard treatment.
The study by Nakata et al. addresses this unmet need by profiling platelet-bound complement components and linking them to platelet-bound immunoglobulins and clinical phenotypes. The work is especially relevant because complement-targeted therapies are being considered in immune-mediated hematologic disease, but patient selection remains a major challenge.
Study Design
This was a clinical biomarker study involving 40 adults with primary ITP. The investigators assessed platelet-bound complement markers, specifically C1q, C3d, and C4d, and compared their levels with healthy controls. They also measured platelet-associated immunoglobulins, including IgG and IgM, and evaluated associations with platelet turnover markers, clinical refractoriness to first-line therapy, plasma C1s ratio, and fatigue scores.
To better define biologic subgroups, the authors applied hierarchical clustering analysis based on complement deposition patterns. This approach is useful for detecting natural groupings in heterogeneous diseases and may reveal endotypes that are not obvious from conventional clinical classification alone.
Although the abstract does not provide detailed statistical parameters such as effect sizes, confidence intervals, or exact P values, the qualitative findings indicate a strong signal of biologic heterogeneity. The study’s value lies less in immediate therapeutic guidance and more in its potential to refine mechanistic understanding and future trial design.
Key Findings
Complement deposition was common but highly variable
Platelet-bound C1q, C3d, and C4d were elevated in a substantial proportion of patients with ITP compared with healthy controls. Importantly, the titer distribution was highly variable, suggesting that complement activation is not a universal feature of ITP but rather a marker of a distinct disease subset. This variability supports the concept that ITP should be considered a syndrome with multiple immune phenotypes rather than a single uniform entity.
Three biologically meaningful clusters emerged
Hierarchical clustering separated patients into three groups: cluster 1, all negative for complement deposition; cluster 2, elevated C1q with negative to low C3d and C4d; and cluster 3, high C3d and C4d. This pattern is biologically informative. C1q is associated with classical pathway initiation, whereas C3d and C4d reflect downstream complement activation and deposition. The presence of isolated or predominant C1q in cluster 2 may suggest early or limited activation, whereas cluster 3 likely reflects more sustained or extensive complement cascade amplification.
Platelet-associated IgM appeared linked to stronger complement activation
Platelet-associated IgM was detected mostly in cluster 3, while platelet-associated IgG was observed in clusters 2 and 3. This difference may be mechanistically important. IgM is a potent activator of the classical complement pathway, so its association with high C3d and C4d deposition provides a plausible explanation for stronger complement activation in cluster 3. By contrast, IgG can also activate complement, but its presence across two clusters suggests it may contribute to a broader range of phenotypes, potentially depending on antibody specificity, density, and subclass distribution.
Complement activation associated with treatment refractoriness
The number of cases refractory to first-line therapy increased in clusters 2 and 3. This is one of the most clinically relevant findings in the study. If replicated, platelet complement deposition could become a marker of treatment-resistant disease and might help identify patients who are less likely to respond to standard initial therapies. For clinicians, this raises the possibility that complement profiling could eventually inform earlier escalation strategies or enrollment into targeted trials.
Complement deposition correlated with increased immature platelets
Complement activation on the platelet surface correlated with a higher percentage of immature platelets, a surrogate of increased platelet turnover. This finding suggests ongoing peripheral platelet destruction with compensatory marrow output. It is consistent with the view that complement activity contributes to immune-mediated clearance rather than isolated marrow suppression. However, increased immature platelets do not fully explain thrombocytopenia severity on their own; they are better interpreted as evidence of dynamic platelet consumption and regenerative response.
No clear relationship with other proposed biomarkers
There was no significant association between complement activation and platelet-associated GPIIb/IIIa or GPIb/IX antibodies, plasma C1s ratio, or fatigue score. This negative result is important because it indicates that complement activation is not simply a surrogate for the commonly measured platelet antibody targets in ITP, at least in this cohort. The lack of association with fatigue also suggests that complement deposition reflects biologic disease activity more than patient-reported symptom burden, although fatigue in ITP is multifactorial and may require separate study.
Expert Commentary
This study strengthens the hypothesis that complement activation defines a clinically relevant subset of adult ITP. The most compelling aspect is the integration of mechanistic biomarker data with clinical phenotyping. Rather than treating complement as a binary presence-or-absence phenomenon, the authors show a graded spectrum of platelet-bound complement deposition that maps onto antibody patterns and treatment response.
From a pathophysiologic standpoint, the findings are plausible. Classical complement pathway activation is well suited to antibody-driven autoimmune disease. Platelet-bound IgM, in particular, is a strong upstream signal that could explain the observed enrichment of downstream C3d and C4d deposition. The association with immature platelets further supports ongoing immune platelet turnover. Together, these data align with a model in which complement amplifies platelet clearance in a subset of patients with active humoral immunity.
Several limitations should temper interpretation. First, the sample size was small, with only 40 patients, which limits precision and the ability to perform robust multivariable analyses. Second, the study design appears cross-sectional, so causality cannot be established. It remains unclear whether complement activation predicts future refractoriness or merely reflects more severe existing disease. Third, the abstract does not provide details on prior treatments, disease duration, bleeding phenotype, or concomitant immunosuppression, all of which could influence biomarker profiles. Fourth, platelet-bound complement assays are technically demanding and not yet standardized for routine clinical use.
Generalizability is another concern. The cohort likely reflects a selected adult ITP population from specialized centers, and the results may not extend to pediatric disease, secondary ITP, or patients with different ethnic or geographic backgrounds. In addition, the absence of an association with plasma C1s ratio suggests that circulating complement measurements may not capture the biologically relevant compartment; surface-bound assays may be more informative, but they are also more complex.
Despite these caveats, the study has meaningful translational implications. Complement-targeted therapies are already established in other immune-mediated hematologic disorders, and the concept of biomarker-guided patient selection is increasingly important in precision medicine. If validated, platelet-bound complement profiling could help stratify patients for trials of complement inhibitors or related immune-modulating strategies. It may also help distinguish patients whose thrombocytopenia is dominated by antibody-complement mediated clearance from those whose disease is driven by other mechanisms such as Fc receptor-mediated phagocytosis or impaired thrombopoiesis.
Clinical Implications
For practicing hematologists, these findings do not yet justify routine complement testing in ITP. However, they do support a more nuanced view of refractory disease. In patients who fail standard first-line therapy, especially those with evidence of rapid platelet turnover, complement activation may be part of the underlying biology. In the future, such patients could be candidates for biomarker-guided trial enrollment or targeted treatment strategies.
More broadly, this work reinforces a central lesson in ITP research: biomarker heterogeneity matters. The field is moving toward endotype-based classification, where immune phenotype, platelet destruction mechanisms, and marrow response are integrated to guide treatment decisions. Complement profiling may become one useful layer in that framework.
Conclusion
Nakata and colleagues provide important evidence that complement activation on the platelet surface identifies a distinct biologic subset of adults with primary ITP. The association with platelet-associated IgM, increased immature platelets, and greater first-line treatment refractoriness suggests that complement is not merely an epiphenomenon but may contribute to clinically meaningful disease heterogeneity. Although these findings require validation in larger, longitudinal cohorts, they offer a strong rationale for incorporating complement biomarkers into future precision-medicine trials in ITP.
Funding and Clinical Trial Registration
The abstract provided does not report funding details or a clinical trial registration number.
References
1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
2. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
3. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995-1008.
4. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2007;44(4 Suppl 5):S3-S11.
5. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura. Blood. 2008;112(4):1147-1152.
6. Nakata K, Onami I, Kato H, Kosugi S, Tomiyama Y, Matsushita H, Kurata A, Sato K, Takahashi K, Sawamura F, Ohmine K, Ohtomo S, Hosen N, Kashiwagi H. Complement activation profile in adult primary immune thrombocytopenia. Blood. 2026;147(24):2958-2969. PMID: 41915761.